Roche/ArQule Enter E2F Oncology Alliance; Roche Licensing Likely At Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
The partnership gives ArQule $15 mil. up-front plus additional funding for its E2F oncology program. The firm hopes to be the first to market with an E2F-targeted agent.